Global Typhoid Fever Vaccines Market Overview
Typhoid Fever Vaccines market size was valued at USD 386.5 Million in 2024 and is expected to reach USD 1092.7 Million by 2034, growing at a CAGR of 12.6%
The typhoid fever vaccines market includes the development, production, and distribution of immunizations designed to protect against Salmonella Typhi, a bacterium that causes typhoid fever. This infectious disease, mostly spread in developing countries because of inefficient sanitation and hygiene, is such that it remains a big problem for public health with great morbidity and mortality. The typhoid vaccines market has grown as the need to prevent this disease gains increasing importance, particularly in regions where there are high endemic rates and among travelers visiting such regions. Typhoid vaccines can be categorized into several types depending on their mechanism of action and the target population. Traditional Vi polysaccharide vaccine has been in use for several decades, offering moderate protection against typhoid fever in adults. On the other hand, it is less effective in children and the elderly. More recently, great advances have been made with the development of conjugate typhoid vaccines. These vaccines linking the Vi polysaccharide to a carrier protein have enhanced immunogenicity and efficacy, principally in young children.
Epidemiological trends, government immunization programs, infrastructure in health care, and economic conditions are what the typhoid vaccine market depends on. Another major factor that has been driving home the need for vaccination as a preventive measure is the rising cases of antibiotic-resistant typhoid pathovars. Besides, the extension of the base of the potential market for typhoid vaccines has resulted from the growing number of international travelers to endemic regions. This market is somewhat limited, as it contains few large players. In this respect, continuous research and development in the area of vaccine efficacy, broadening age indications, and decreasing production cost is going on. As the world continues to bear a heavy burden from typhoid fever, demand for effective and affordable vaccines is likely to increase, hence expanding the market. New vaccine formulations and delivery systems could further open up more opportunities. Thus, the typhoid fever vaccines market is an integral part of global health initiatives geared toward the control and elimination of diseases that are extremely easy to prevent. These vaccines provide protection against typhoid and thereby reduce morbidity, mortality, and health expenditure on account of the disease.
For More Report Details, Download Free Sample PDF
Global Typhoid Fever Vaccines Market Drivers & Restraints
Key Drivers of Target Market:
High Prevalence in Endemic Countries
- Typhoid fever continues to be an important health problem in parts of Asia, Africa, and Latin America. These high incidence rates create demand for vaccination programs that have the capability to control and prevent outbreaks in endemic regions. Raising awareness regarding typhoid fever, its symptoms, and preventive measures amongst the population in endemic areas and travelers has increased demand for the vaccines. This may be due to public health campaigns and educational efforts.
Advancing Vaccine Technologies
- Major advances in vaccine technology, of which the development of conjugate vaccines is the most prominent example, have contributed to more effective and safe typhoid vaccines. This has led to an increase in their uptake and use in national immunization programs. Governments and international organizations, such as WHO and Gavi, the Vaccine Alliance, financing and supporting vaccination programs in high-risk regions, facilitate access to vaccines.
Restrains:
Poor Infrastructure for Healthcare
- Most endemic regions have a poor healthcare infrastructure that inhibits the process of distribution and administration of vaccines. Issues that derail vaccination efforts include lack of refrigeration, a lack of health workers, and trained vaccinators. Misinformation and a general lack of trust in vaccines increase vaccine hesitancy among populations, hence reducing the uptake for typhoid vaccines. Cultural beliefs, generalized mistrust, and fear of possible side effects are some of the causes of this challenge.
Opportunities:
Immunization Program Expansion:
- Huge potential exists for the expansion of national immunization programs to include vaccination against typhoid, more so after the availability of more effective conjugate vaccines. This can be accompanied by an increased vaccination coverage and disease control. Government-to-government or international organization-to-private sector firms collaboration in the production, distribution, and administration of vaccines could make the vaccines more accessible and affordable, thereby increasing their intake.
Global Typhoid Fever Vaccines Market Segmentations & Regional Insights
The market is segmented based on Vaccine Type, Route of Administration, End-User, and Region.
Vaccine Type Insights:
- Live Attenuated Vaccine: Live attenuated vaccines have a weakened form of the typhoid bacteria Salmonella Typhi that induces an immune response in the body without causing typhoid fever in an individual. One such live attenuated vaccine is Ty21a, which is administered orally and is one of the most popular amongst all. This type of vaccine has the advantage of usually requiring fewer doses and often providing long-lasting immunity. However, live vaccines are contraindicated in immunocompromised people because there is a risk of the attenuated bacteria is causing illness in these individuals. They must be kept under strict conditions to have the best effect and this can be a problem in areas without access to refrigeration.
- Inactivated vaccines have killed bacteria and hence cannot lead to disease. One common example is the Vi capsular polysaccharide vaccine. They are normally given via injection and considered far safer for people with compromised immunity compared to live vaccines. While they tend to have fewer side effects, inactivated vaccines might require booster shots to keep up immunity over time. The simplicity of their storage requirements also makes them more suitable for use in regions with limited healthcare infrastructure.
- Conjugate Vaccine: A new generation of vaccine that links the polysaccharide antigen from the bacteria to the carrier protein, improving the immune response, mostly in young children and infants. One example is the Typhoid Conjugate Vaccine, designed to provide longer-lasting immunity, and to be more effective in younger age groups than polysaccharide vaccines alone. These vaccines are generally administered by injection and are increasingly used in national immunization programs as their effectiveness and safety profile is superior to that of the previous ones.
Route of Administration Insights:
- Oral typhoid vaccines, like the live attenuated Ty21a, are taken orally, particularly in areas of high typhoid fever prevalence. Their ease of administration, without use of needles, makes them more favorable for people fearing injections. Oral vaccines, however, require multiple doses over a period of time, and adhering to the schedule is very important in achieving full immunity.
- Injection: Both inactivated and conjugate vaccines are given either intramuscularly or subcutaneously. Such vaccines are preferred due to the rapid administration and are easy to administer in controlled settings, such as in hospitals and clinics. Injected vaccines need fewer doses and similar doses have more consistent immune responses compared to oral vaccines. These vaccines are recommended for routine immunization schedules and can be given with other vaccines.
End-User Insights:
- Hospitals: This implies that the major centers of typhoid vaccine administration are hospitals, particularly in high-risk populations such as healthcare workers, patients with chronic diseases, and travelers. This is possible because the infrastructure available at a hospital will help in proper storage, administration, and follow-up that may be required for the process of immunization and monitoring for adverse effects.
- Clinics: These clinics, be it private or public healthcare facilities, also play a pivotal role in administering typhoid vaccines, especially in rural and underserved areas. Most of them are accessible points for routine immunization and offer vaccination for the people coming for preventive care. Clinics often collaborate with public health agencies in the delivery of vaccines under general immunization campaigns.
- Public health authorities should organize and carry out mass vaccination against typhoid fever, especially in areas where the infection is endemic. It accomplishes its work through the coordination of vaccine supplies, raising awareness among the people, and ensuring maximum coverage. The monitoring of vaccine supplies, managing stocks, and addressing logistics in order to reach peripheral high-risk populations is also done.
- Travel clinics focus on vaccination and health guidance for travelers, with special attention to those traveling to areas where typhoid fever has a high endemicity. Travel clinics provide focused vaccination services depending on the destination and risk assessment for the traveler. Other services that travel clinics offer include education on preventive measures and travel health risks; therefore, the travelers will be fully empowered with information on how to protect themselves against typhoid fever.
By Regional Insights:
- North America: typhoid vaccination is majorly recommended for travelers to areas where typhoid fever is endemic. In this region, the market is driven by travel health services, awareness campaigns, and public health recommendations. High healthcare standards and infrastructure facilitate the easy and proper distribution and administration of vaccines.
- Europe: Similar to North America, the typhoid vaccine market in Europe has been driven primarily by travel-related demand. Furthermore, European countries target immigrant and refugee populations from typhoid-endemic regions. Strong public health systems and comprehensive immunization programs underpin this market growth.
- The Asia-Pacific region has a high burden of typhoid fever, particularly in countries such as India, Pakistan, and Bangladesh. This region presents a significant demand for all kinds of typhoid vaccines because of the high prevalence of the disease in this region. The broad distribution and dispensation of vaccines are motivated by national immunization programs and international support.
- Latin America: Countries with moderate to high prevalence rates for typhoid fever include the nations from Latin America. Thus, a part of public health strategy in countries across Latin America is vaccination against typhoid infection. It is used mainly in areas where sanitation and water quality are low. Public health initiatives and travel vaccination services boost the market in this region.
- In the Middle East and Africa, typhoid fever persists as a significant public health problem. The requirement for routine immunization programs, particularly where access to pure water and sanitation is poor, helps drive the market in the Middle East and Africa. International aid and public health campaigns are key to vaccine distribution and administration across these regions.
Typhoid Fever Vaccines Market Report Scope:
Attribute |
Details |
Market Size 2024 |
USD 386.5 Million |
Projected Market Size 2034 |
USD 1092.7 Million |
CAGR Growth Rate |
12.6% |
Base year for estimation |
2023 |
Forecast period |
2024 – 2034 |
Market representation |
Revenue in USD Million & CAGR from 2024 to 2034 |
Market Segmentation |
By Vaccine Type- Live Attenuated Vaccine, Inactivated (Killed) Vaccine, Conjugate Vaccine By Route of Administration- Oral, Injection By End-User- Hospitals, Clinics, Public Health Agencies, Travel Clinics |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Vaccine Type, Route of Administration, End-User, and Region.
Segmentation:
By Vaccine Type:
- Live Attenuated Vaccine
- Inactivated (Killed) Vaccine
- Conjugate Vaccine
By Route of Administration:
- Oral
- Injection
By End-User:
- Hospitals
- Clinics
- Public Health Agencies
- Travel Clinics
By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Global Typhoid Fever Vaccines Market Competitive Landscape & Key Players
The key players operating the Typhoid Fever Vaccines Market include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech International Limited, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc., Shanghai Institute of Biological Products Co., Ltd., and Prokarium Ltd.
Global Typhoid Fever Vaccines Market Recent News
- In November 2023, biotech firm has just come out with a new single-dose typhoid vaccine to make immunization much easier and more compliant. The chances of increased vaccination coverage, particularly at locations where vaccination is hampered by logistical constraints, are very bright.
- In February 2024, new oral typhoid vaccine for children below five years was cleared by the Indian regulatory authorities. This vaccine meets the long-standing need for a child-friendly vaccine formulation, which will increase vaccination rates in young children.
- June 2024, it was announced that a leading vaccine manufacturer would collaborate with an African biotech firm in establishing local production facilities for typhoid vaccines. This collaboration will help strengthen regional capabilities for the manufacture of vaccines and supply sustainability in African countries.
Global Typhoid Fever Vaccines Market Company Profile
- GlaxoSmithKline Plc.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Sanofi SA
- Bharat Biotech International Limited
- Bio-Med Pvt. Ltd.
- PT Bio Farma
- PaxVax, Inc.
- Shanghai Institute of Biological Products Co., Ltd.
- Prokarium Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
FAQs
Typhoid Fever Vaccines Market Size was valued at USD 386.5 Million in 2024 and is expected to reach USD 1092.7 Million by 2034, growing at a CAGR of 12.6%
Typhoid Fever Vaccines Market is segmented into Vaccine Type, Route of Administration, End-User, and Region.
Factors driving the market include High Prevalence in Endemic Countries and Advancing Vaccine Technologies.
The Typhoid Fever Vaccines Market's restraints include Poor Infrastructure for Healthcare.
The Typhoid Fever Vaccines Market is segmented by Region into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America is expected to dominate the Market.
The key players operating the Typhoid Fever Vaccines Market include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech International Limited, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc., Shanghai Institute of Biological Products Co., Ltd., and Prokarium Ltd.